MedTrace Logo

Phase 2 Study of SJX-653 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms

NCT04278872 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2022-01-11

Study results available
· View outcomes & findings →

Summary

This study evaluates the efficacy, safety, tolerability, and pharmacokinetics of once daily SJX-653 in postmenopausal women with moderate to severe VMS.

Conditions

Interventions

DRUG

SJX-653

administered orally once daily

DRUG

Placebo

administered orally once daily

Sponsors & Collaborators

  • Sojournix, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Sojournix, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-09
Primary Completion
2021-02-12
Completion
2021-04-07

Countries

  • Belgium
  • Germany
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04278872 on ClinicalTrials.gov